Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial.

Clinical trial NCT07421856 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07421856
Sponsor: Hebei Senlang Biotechnology Inc., Ltd.
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Multiple Myeloma in Relapse Multiple Myeloma Refractory

Start date: 2026-02-01
Primary completion: 2028-02-01
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.